Functional consequences of mutations in spliceosomal small nuclear RNAs
剪接体小核RNA突变的功能后果
基本信息
- 批准号:10468151
- 负责人:
- 金额:$ 47.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-08-01 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAge-MonthsAllelesArchitectureBar CodesBiochemicalBiochemistryBiological AssayBrainCandidate Disease GeneCell LineCell SurvivalCellsCerebrumCharacteristicsCompetenceComplementary DNADefectDevelopmentDiabetes MellitusDiseaseEmbryoEngineeringExcisionFrequenciesGene ExpressionGeneral PopulationGenesGenetic PolymorphismGenomicsGenotypeGoalsGrowthHealthHumanHuman BiologyImmune System DiseasesIntronsKnowledgeLightLinkLowry-Wood syndromeMammalsMental deficiencyMethodsMicrocephalyMigration AssayMinorModelingMolecularMolecular AnalysisMusMutant Strains MiceMutationNeuronsOrganOrganoidsPancreasPathogenesisPathogenicityPathologyPatientsPatternPhenotypePoint MutationPopulationRNA Primary TranscriptRNA SplicingRoleSingle Nucleotide PolymorphismSmall Nuclear RNASpliceosomesSuggestionSurfaceSyndromeSystemTechniquesTestingTissue-Specific SplicingTissuesTranscriptTransgenesUntranslated RNAVariantbasecell growthcell typedevelopmental diseasedisease-causing mutationhuman diseasehuman migrationhuman modelimprovedin vivoinduced pluripotent stem celllissencephalymRNA Precursormigrationmouse modelmutantosteodysplastic primordial dwarfismpancreas developmentpuprestorationskeletal abnormalitytooltranscriptome sequencing
项目摘要
Project Summary
The removal of introns from pre-mRNA transcripts is an essential step in the expression of almost all human
genes. The goal of this project is to determine the molecular, cellular and tissue-specific consequences of
mutations in the U4atac snRNA gene (RNU4ATAC) that are the cause of the rare and severe human
developmental disorders microcephalic osteodysplastic primordial dwarfism type I (MOPD I), Roifman
Syndrome (RS) and Lowry-Wood Syndrome (LWS). U4atac snRNA is required for the splicing of minor class
U12- dependent introns. Genes containing these introns are poorly spliced in MOPD I and RS patient cells. We
hypothesize that the various pathologies seen in MOPD I, RS and LWS are caused by reduced splicing or mis-
splicing of a small number of genes containing U12-dependent introns. In addition, we have found that the
RNU4ATAC gene, as well as other snRNA genes, harbor large numbers of low frequency single nucleotide
polymorphisms in all human populations, supplying a mutational origin for these recessive disorders. We have
developed cell lines, including patient-derived and gene-edited human iPS cells, and new assay systems to
investigate the specific defect(s) in splicing caused by the mutations. 1) We will use these cell lines to analyze
the effects of all possible U4atac snRNA mutations on cell growth using a high-throughput method. Based on
these results and the mutations observed in patients with the different syndromes, we will generate cell lines
homozygous for various mutations and employ biochemical techniques to characterize their functional defects.
2) We will determine the differentiation potential of human iPS cells with a variety of disease-linked mutations.
For example, since severe MOPD I is characterized by microcephaly and lissencephaly, we are using MOPD I
patient-derived human iPS cells to generate and study cerebral brain organoids. We have also generated
mouse mutant U4atac models that recapitulate many MOPD I pathologies. They also develop severe diabetes
by two months of age. We will study the cellular phenotypes of the mouse pancreas as the disease develops to
characterize the developmental disorder. 3) We will use RNA-seq and other molecular analyses of human cells
and mouse tissues to relate specific pathologies to defects in splicing of target genes. These targets will be
validated through restoration of gene expression by properly spliced cDNA. Successful completion of these
studies will advance our understanding of spliceosomal splicing, define the molecular causes of human
diseases and determine the role of U12-dependent splicing in gene expression and development.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MAURA L GILLISON其他文献
MAURA L GILLISON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MAURA L GILLISON', 18)}}的其他基金
PREVALENCE AND DETERMINANTS OF ORAL HPV INFECTION IN THE US POPULATION
美国人口腔 HPV 感染的患病率和决定因素
- 批准号:
8087141 - 财政年份:2012
- 资助金额:
$ 47.25万 - 项目类别:
PREVALENCE AND DETERMINANTS OF ORAL HPV INFECTION IN THE US POPULATION
美国人口腔 HPV 感染的患病率和决定因素
- 批准号:
8476211 - 财政年份:2012
- 资助金额:
$ 47.25万 - 项目类别:
A Therapeutic Vaccine for HPV 16-Positive Head and Neck Cancer
HPV 16 阳性头颈癌的治疗疫苗
- 批准号:
7224465 - 财政年份:2007
- 资助金额:
$ 47.25万 - 项目类别:
A Therapeutic Vaccine for HPV 16-Positive Head and Neck Cancer
HPV 16 阳性头颈癌的治疗疫苗
- 批准号:
7360307 - 财政年份:2007
- 资助金额:
$ 47.25万 - 项目类别:
HUMAN ORAL PAPILLOMAVIRUS ETIOLOGY (HOPE) STUDY
人类口腔乳头状病毒病因学(希望)研究
- 批准号:
7604671 - 财政年份:2006
- 资助金额:
$ 47.25万 - 项目类别:
OSI-774 IN PATIENTS WITH ORAL CAVITY OR OROPHARYNGEAL CANCER
OSI-774 用于口腔癌或口咽癌患者
- 批准号:
7604553 - 财政年份:2006
- 资助金额:
$ 47.25万 - 项目类别:
OSI-774 IN PATIENTS WITH ORAL CAVITY OR OROPHARYNGEAL CANCER
OSI-774 用于口腔癌或口咽癌患者
- 批准号:
7378807 - 财政年份:2005
- 资助金额:
$ 47.25万 - 项目类别: